Promega is launching a post-doctoral research program for life science researchers to explore new ideas for genome engineering technology, the company announced today.

AstraZeneca will provide mentoring support in the three-year program that takes place at the AstraZeneca R&D site in Gothenburg, Sweden, and at Promega’s headquarters.

“We’re thrilled to invest directly in people dedicated to outcomes beneficial to science and human health,” Promega Advanced Technologies Group Director of Research Thomas Machleidt said in a statement. “The collaborative approach allows us to leverage our respective strengths alongside our colleagues at AstraZeneca and provide unparalleled access to tools and expertise that will expand what is possible with genome editing.”

According to a release, the program gives researchers the unique opportunity to work on groundbreaking projects in an emerging field while collaborating with scientists at a global pharmaceutical company and a manufacturer of life science research tools.

Applicants must have a PhD in molecular/cell biology/genetics and broad multidisciplinary experience.